Teicoplanin-TF (Teicoplanin)
Powder for solution for intravenous and intramuscular administration 200 mg, 400
Description
New highly effective glycopeptide antibiotic for systemic use with bactericidal activity against a wide range of gram-positive (+) bacteria, multiresistant nosocomial strains, including VanB-phenotype VRE. It can be administered once daily intramuscularly or intravenously as a bolus injection. The antibiotic has low toxicity and favorable tolerability. It is used in treatment of serious respiratory and urinary tract infections, skin and soft tissue infections, bone and joint infections, septicemia, endocarditis, peritonitis, infectious colitis.
- Medical Equipment
- antibiotics
- Powder for solution for intravenous and intramuscular administration 200 mg, 400 mg
- Glycopeptides
Similar products from JLLC «TRIPLEPHARM»
JLLC «TRIPLEPHARM»
Belarus
First antibiotic of the glycopeptide group. Highly active against a wide range of gram-positive (+) microorganisms, including methicillin-resistant strains. Used in treatment of endocarditis, sepsis, skin and soft tissue infections, bone and joint infections (including osteomyelitis), CNS infections (including meningitis), infections of lower respiratory tract, pseudomembranous colitis, enterocolitis.
JLLC «TRIPLEPHARM»
Belarus
An effective bactericidal antibiotic for the treatment of infections caused by gram-negative and gram-positive bacteria. It has a bactericidal effect on proliferating pathogenic microorganisms, preventing the enzymatic synthesis of the bacterial cell wall.
JLLC «TRIPLEPHARM»
Belarus
Antituberculous polypeptide antibiotic with low toxicity and and good tolerance. It is used for the treatment of drug-resistant forms of pulmonary tuberculosis.
JLLC «TRIPLEPHARM»
Belarus
The active ingredient of Claribaccin is clarithromycin. Clarithromycin is a semisynthetic macrolide antibiotic derived by substitution of CN3O hydroxyl group by (OH) group in the 6th position of the lactone ring of erythromycin, more precisely, clarithromycin is 6-Omethylerythromycin A. The mechanism of action of clarithromycin is based on binding to 50S ribosomal subunit of sensitive bacteria, which prevents the translocation of activated amino acids. Clarithromycin inhibits intracellular protein synthesis of microorganisms sensitive thereto and thereby exerts its antibacterial action.